Plain-English translation of NCT06940960 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new treatment called JY231 for people with advanced B-cell lymphomas and leukemias that have stopped responding to standard chemotherapy. JY231 works by training your own immune cells to recognize and attack cancer cells. The study will follow you for up to 24 months to see if the treatment is safe and whether it helps control your cancer.
People whose blood cancers have returned or become resistant to standard treatments have limited options and often face a poor prognosis. This trial exists to see if this new cell-based therapy can offer hope to patients who have run out of other effective options.
You likely qualify if…
You likely don't qualify if…
First, you will undergo a procedure called leukapheresis, where blood is drawn and your immune cells are collected and sent to a laboratory. You will then receive chemotherapy drugs (fludarabine and cyclophosphamide) for 3–5 days to prepare your body. After that, you will receive an intravenous infusion of the medication. You will then be closely monitored with regular clinic visits, blood tests, and scans for up to 24 months to check for side effects and whether your cancer is responding.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China